<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>礼来公司（LLY）周四宣布了第三阶段 ATTAIN-MAINTAIN 试验的积极顶线结果，该试验评估了 orforglipron 在先前接受 Wegovy 或 Zepbound 治疗的参与者中的体重维持效果。</p>
<p>在这项随机、双盲的试验中，公司评估了每日一次的 orforglipron 与安慰剂在减重维持方面的疗效和安全性，参与者为肥胖或超重且有体重相关合并症的成年人。</p>
<p>在 52 周结束时，orforglipron 达到了主要终点，即与安慰剂相比，体重减轻维持的百分比显著优越。值得注意的是，从 Wegovy 切换到 orforglipron 的参与者平均保持了 0.9 公斤的体重损失，而从 Zepbound 切换到 orforglipron 的参与者平均保持了 5.0 公斤的体重损失。</p>
<p>鉴于如此积极的结果，该制药公司已向美国食品药品监督管理局提交了 orforglipron 的新药申请，旨在治疗肥胖或超重的成年人。</p>
<p>公司预计将在未来的医学会议上展示 ATTAIN-MAINTAIN 试验的详细结果，并将在明年发表在同行评审的期刊上。</p>
<p>在盘前交易时，LLY 的交易价格为 1,044.94 美元，较纽约证券交易所上涨 0.32%。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

礼来

<p>礼来宣布其针对 orforglipron 的第三阶段 ATTAIN-MAINTAIN 试验取得积极结果，该药物用于维持曾接受 Wegovy 或 Zepbound 治疗的成年人的体重。试验显示 orforglipron 在维持体重减轻方面的有效性，这导致了向 FDA 提交新药申请。详细结果将在未来的医学会议上公布。LLY 股票在盘前交易中上涨了 0.32%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Eli Lilly and Company (LLY), Thursday announced positive topline results from the Phase 3 ATTAIN-MAINTAIN trial, which evaluated orforglipron for weight maintenance in participants who were earlier treated with Wegovy or Zepbound.</p>
<div class="lb-trans"><p>礼来公司（LLY）周四宣布了第三阶段 ATTAIN-MAINTAIN 试验的积极顶线结果，该试验评估了 orforglipron 在先前接受 Wegovy 或 Zepbound 治疗的参与者中的体重维持效果。</p>
</div><p>During the randomized, double-blind trial, the company evaluated efficacy and safety of once-daily orforglipron versus placebo for maintenance of body weight reduction in adults with obesity or overweight with weight-related comorbidities.</p>
<div class="lb-trans"><p>在这项随机、双盲的试验中，公司评估了每日一次的 orforglipron 与安慰剂在减重维持方面的疗效和安全性，参与者为肥胖或超重且有体重相关合并症的成年人。</p>
</div><p>At the end of 52 weeks, orforglipron met the primary endpoint of superior percent maintenance of body weight reduction compared to placebo. Notably, participants who switched to orforglipron from Wegovy maintained their previously achieved weight loss with an average difference of 0.9 kg, while those who switched to orforglipron from Zepbound maintained their previously achieved weight loss with an average difference of 5.0 kg.</p>
<div class="lb-trans"><p>在 52 周结束时，orforglipron 达到了主要终点，即与安慰剂相比，体重减轻维持的百分比显著优越。值得注意的是，从 Wegovy 切换到 orforglipron 的参与者平均保持了 0.9 公斤的体重损失，而从 Zepbound 切换到 orforglipron 的参与者平均保持了 5.0 公斤的体重损失。</p>
</div><p>In light of such positive findings, the medicine company has submitted a new drug application to the U.S. Food and Drug Administration for orforglipron for the treatment of adults with obesity or overweight.</p>
<div class="lb-trans"><p>鉴于如此积极的结果，该制药公司已向美国食品药品监督管理局提交了 orforglipron 的新药申请，旨在治疗肥胖或超重的成年人。</p>
</div><p>The company expects to present the detailed results from the ATTAIN-MAINTAIN trial at a future medical meeting and published in a peer-reviewed journal next year.</p>
<div class="lb-trans"><p>公司预计将在未来的医学会议上展示 ATTAIN-MAINTAIN 试验的详细结果，并将在明年发表在同行评审的期刊上。</p>
</div><p>In the pre-market hours, LLY is trading at $1,044.94, up 0.32 percent on the New York Stock Exchange.</p>
<div class="lb-trans"><p>在盘前交易时，LLY 的交易价格为 1,044.94 美元，较纽约证券交易所上涨 0.32%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

礼来的 Orforglipron 在 3 期 ATTAIN-MAINTAIN 试验中展现出积极的试验数据